Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Accumulated Expenses (2016 - 2025)

Agios Pharmaceuticals' Accumulated Expenses history spans 14 years, with the latest figure at $45.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 2.99% year-over-year to $45.5 million; the TTM value through Dec 2025 reached $45.5 million, down 2.99%, while the annual FY2025 figure was $45.5 million, 2.99% down from the prior year.
  • Accumulated Expenses reached $45.5 million in Q4 2025 per AGIO's latest filing, up from $37.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $46.9 million in Q4 2024 to a low of $19.7 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $31.8 million, with a median of $30.4 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: crashed 41.21% in 2021, then surged 42.23% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $32.0 million in 2021, then dropped by 5.06% to $30.4 million in 2022, then soared by 42.23% to $43.2 million in 2023, then rose by 8.56% to $46.9 million in 2024, then fell by 2.99% to $45.5 million in 2025.
  • Per Business Quant, the three most recent readings for AGIO's Accumulated Expenses are $45.5 million (Q4 2025), $37.2 million (Q3 2025), and $35.3 million (Q2 2025).